February 19, 2016 News by Margarida Azevedo, MSc Research on Progressive MS to Be Funded by International Progressive MS Alliance Dr. Timothy Coetzee from the National Multiple Sclerosis Society will present an overview of the objectives and achievements of the International Progressive MS Alliance (PMSA), an organization dedicated to facilitating and funding research on progressive multiple sclerosis (MS), a form of MS especially lacking effective therapeutic options. Coetzee…
February 19, 2016 News by Patricia Silva, PhD Progressive MS Trials May Need a ‘Tailored’ MRI Approach, Researcher Tells ACTRIMS 2016 Dr. Daniel S. Reich with Johns Hopkins University is giving an oral talk on “MRI as an Outcome Measure in Progressive Multiple Sclerosis” at Friday’s ACTRIMS Forum 2016. This year’s meeting focuses on progressive MS, and runs through Saturday, Feb. 20, in New Orleans. Magnetic resonance imaging (MRI) has been the…
February 18, 2016 News by Margarida Azevedo, MSc NIH Study into Progressive MS Biomarkers to Be Presented at ACTRIMS 2016 Scientists from the Neuroimmunological Diseases Unit at the National Institutes of Health (NIH) will present results of a study investigating several biomarkers that might lead to a more sensitive and accurate diagnostic test of central nervous system (CNS) inflammation, a key aspect of progressive multiple sclerosis (MS). The data is being reported today, Feb.18, at the…
February 1, 2016 News by Patricia Silva, PhD Protein Seen to Impede Remyelination in Multiple Sclerosis Patients Researchers from Karolinska Institute, Sweden, reported that the immune-associated protein lipocalin-2 (LCN2) is increased in multiple sclerosis, particularly in patients with progressive MS. The researchers, however, concluded that the factor cannot be used as a biomarker for the disease. The study, “Lipocalin-2 is increased in progressive multiple sclerosis…
November 20, 2015 News by Patricia Silva, PhD MS Society Funds 5 Projects Aiming to Cure the Disease The Multiple Sclerosis Society (MS Society) in the United Kingdom recently announced the investment of £1.98 million in new MS research. After an in-depth, rigorous review process of the 58 applications submitted, 16 projects were awarded funding through the MS Society’s 2015 grant round totaling £1,979,879. All applications…
August 6, 2015 News by Patricia Silva, PhD New MS Testing Model Can Predict If Disease Will Intensify in Patients A new study published in the journal Statistical Methods in Medical Research revealed a new method to determine the disease course in multiple sclerosis (MS) patients. The study is entitled “Joint assessment of dependent discrete disease state processes” and was conducted by researchers at…
June 23, 2015 News by Patricia Silva, PhD MedDay Reveals Promising Data on Progressive Multiple Sclerosis Therapy MedDay, a biotechnology company dedicated to developing therapies for nervous system disorders, recently announced encouraging data on its pivotal Phase III clinical trial (MS-SPI) assessing the safety and efficacy of the company’s investigational therapy MD1003 for the treatment of progressive multiple sclerosis (MS). The data was presented at The…
May 25, 2015 News by Maureen Newman New Compound Tested in Lab Shows Promise for Progressive Multiple Sclerosis Exploratory research conducted at Virginia Commonwealth University and the University of Illinois at Chicago may translate into a new therapeutic agent to treat progressive multiple sclerosis. Researchers in the laboratories of Dr. Jefferey L. Dupree and Dr. Douglas L. Feinstein tested a new compound in mice with induced multiple sclerosis…
May 22, 2015 News by Patricia Silva, PhD Progressive MS Challenges to Be Dicussed at CMSC Meeting The needs of patients who suffer from progressive multiple sclerosis (MS) will be addressed in a presentation hosted by Alan Thompson, MD, FRCP, from the University College London (UCL) during the Donald Paty Memorial Lecture. The Lecture will take place during the Consortium of Multiple Sclerosis Centers (CMSC) 29th Annual…
March 13, 2015 News by admin Two Progressive MS Phase III Trials to be Presented at AAN Annual Meeting Myelin — the fatty substance that wraps around nerve cells — is lost in multiple sclerosis (MS). Is there any way to get it back or to stop the deterioration of myelin? Researchers at MedDay Pharmaceuticals think that their drug may provide the solution. Known as MD1003, the…
